Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: Systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 382-395

  Nemeth, Johannes ^a   Oesch, Gabriela ^b   Kuster, Stefan P ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Drug classes; Generalizability; Mechanism of action

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; LINEZOLID; MACROLIDE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; STREPTOGRAMIN DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ARTICLE; BACTERIAL INFECTION; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; COMPARATIVE STUDY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; BACTERIAL INFECTIONS; CLASSIFICATION; RECURRENT DISEASE; RISK; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84922456238     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku379     Document Type: Article

References (50)

1. Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30: 2369-413.
2. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
3. Cohen J, Powderly WG, Opal SM et al. Infectious Diseases, 2 vols. Mosby, 2003.
4. Fauci A, Dennis L, Longo D et al. Harrison's Principles of Internal Medicine. McGraw-Hill Professional, 2008.
5. Cubist Pharmaceuticals Inc. Lexington, MA, USA. http://www.cubicin. com/about.html.
6. Wunderink RG, Niederman MS, Kollef MH et al. Linezolid in methicillinresistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54: 621-9.
7. Itani KM, Dryden MS, Bhattacharyya H et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010; 199: 804-16.
8. Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41: 1407-15.
9. Kohno S, Yamaguchi K, Aikawa N et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007; 60: 1361-9.
10. Lin DF, Zhang YY, Wu JF et al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents 2008; 32: 241-9.
11. San Pedro GS, Cammarata SK, Oliphant TH et al. Linezolid versus ceftriaxone/ cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002; 34: 720-8.
12. Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44: 3408-13.
13. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717-25.
14. Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. http://handbook.cochrane.org/.
15. Bergallo C, Jasovich A, Teglia O et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009; 63: 52-61.
16. Bohte R, van't Wout JW, Lobatto S et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995; 14: 182-7.
17. Dartois N, Castaing N, Gandjini H et al. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother 2008; 20 Suppl 1: 28-35.
18. Genne D, Siegrist HH, Humair L et al. Clarithromycin versus amoxicillinclavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1997; 16: 783-8.
19. Kuzman I, Dakovic-Rode O, Oremus M et al. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. J Chemother 2005; 17: 636-42.
20. Mehtar S, Parr JH, Morgan DJ. A comparison of cefuroxime and co-trimoxazole in severe respiratory tract infections. J Antimicrob Chemother 1982; 9: 479-84.
21. Mokabberi R, Haftbaradaran A, Ravakhah K. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. J Clin Pharm Ther 2010; 35: 195-200.
22. Plouffe J, Schwartz DB, Kolokathis A et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000; 44: 1796-802.
23. Shanson DC, McNabb WR, Williams TD et al. Erythromycin compared with a combination of ampicillin plus flucloxacillin for the treatment of community acquired pneumonia in adults. J Antimicrob Chemother 1984; 14: 75-9.
24. Sterner G, Fransen H, Tunevall G et al. A comparative trial of cephaloridine and erythromycin in hospitalized pneumonic patients. Postgrad Med J 1967; 43 Suppl 43: 53-4.
25. Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-38.
26. Tanaseanu C, Milutinovic S, Calistru PI et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009; 9: 44.
27. Bernard P, Plantin P, Roger H et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992; 127: 155-9.
28. Breedt J, Teras J, Gardovskis J et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658-66.
29. Chuang YC, Chang CM, Aradhya S et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. J Microbiol Immunol Infect 2011; 44: 116-24.
30. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
31. Sacchidanand S, Penn RL, Embil JM et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-61.
32. Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44: 3408-13.
33. Chen Z, Wu J, Zhang Y et al. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis 2010; 10: 217.
34. Oliva ME, Rekha A, Yellin A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5: 88.
35. Qvist N, Warren B, Leister-Tebbe H et al. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial. Surg Infect 2012; 13: 102-9.
36. Towfigh S, Pasternak J, Poirier A et al. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect 2010; 16: 1274-81.
37. Frenck RW Jr, Nakhla I, Sultan Y et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis 2000; 31: 1134-8.
38. Kohno S, Yamaguchi K, Aikawa N et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007; 60: 1361-9.
39. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390-8.
40. MwengeeW, Butler T, Mgema S et al. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis 2006; 42: 614-21.
41. OdeB, CronbergS, FlamholcLet al. Intravenous mecillinam, trimethoprim and ampicillin in acute pyelonephritis. Drugs Exp Clin Res 1983; 9: 337-43.
42. Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis 1999; 18: 199-202.
43. Tasina E, Haidich AB, Kokkali S et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-44.
44. Ramirez J, Dartois N, Gandjini H et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; 57: 1756-62.
45. Cho SY, Kang CI, Chung DR et al. Breakthrough bacteremia due to extended-spectrum-β-lactamase-producing Klebsiella pneumoniae during combination therapy with colistin and tigecycline. Antimicrob Agents Chemother 2012; 56: 4994-5.
46. Mandell G, Bennett J, Dolin R. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone, 2010.
47. Jaksic B, Martinelli G, Perez-Oteyza J et al. Efficacyand safetyof linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42: 597-607.
48. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004; 38: 864-70.
49. Buyck JM, Plesiat P, Traore H et al. Increased susceptibility of Pseudomonas aeruginosa tomacrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability. Clin Infect Dis 2012; 55: 534-42.
50. Drusano GL, Liu W, Fikes S et al. Interaction of drug- and granulocytemediated killing of Pseudomonas aeruginosa in a murine pneumonia model. J Infect Dis 2014; doi:10.1093/infdis/jiu237.